T1022 Infliximab as Rescue Medication for Patients With Severe Ulcerative/Indeterminate Colitis Refractory to Tacrolimus and Vice Versa
Klaus Herrlinger(Robert Bosch Hospital), Klaus Fellermann(Apple (Israel)), Jan Wehkamp(Robert Bosch Hospital), Klaus J. Schmidt(University Gastroenterology), Daniel Nicolas Barthel(Robert Bosch Hospital), Eduard F. Stange(John Radcliffe Hospital), Christiane Barthel, Jürgen Büning(University Hospital Schleswig-Holstein)
Cited by 0
Related Papers
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566
European evidence-based Consensus on the management of ulcerative colitis: Current management
|Journal of Crohn s and Colitis|2008|558